• Home
  • Study Details

PACES - Colorectal Cancer Prevention

To assess whether the combination of eflornithine and sulindac is effective in reducing the three-year event rate (high-risk adenomas and second primary colorectal cancers) in patients with previously treated Stage 0-III colon or rectal cancer.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female


North Carolina (Edgecombe, Nash)

What will be asked of you

1 Optional Diet and Lifestyle Questionnaire

In-person visits : 18
Phone or online visits : 1
Total length of participation : 8 years total (3 years treatment + 5 years follow-up)

Looking for Specific Volunteers

Able to participate:

  • History of Stage 0-III colon or rectal cancer with primary resection 1 year previously
  • At least 30 days from completion of adjuvant chemo and RT.
  • Zubrod PS 0-1

Not eligible if:

  • Planned radiation therapy or additional chemotherapy, IV steroids, or if you are taking NSAID pain relievers regularly or on blood thinning medication.
  • Have uncontrolled hyperlibidemia or a history of heart attack, stroke, or coronary artery bypass surgery.
  • History of colon resection, mid-low rectal cancer, or recurrent or metastatic disease
  • Documented history of gastric/duodenal ulcer within last 12 months and/or current treatment or active symptoms of gastric/duodenal ulcer
  • Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or inflammatory bowel disease

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Devena Alston Johnson
UNC Hospitals - Nash

Study Topics

Cancer (Colorectal)

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.